C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.925
-0.125 (-3.09%)
Nov 21, 2024, 3:04 PM EST - Market open
C4 Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 33.67 | 20.76 | 31.1 | 45.79 | 33.2 | 21.38 | Upgrade
|
| Revenue Growth (YoY) | 65.45% | -33.25% | -32.08% | 37.93% | 55.25% | 10.42% | Upgrade
|
| Cost of Revenue | 108.52 | 117.71 | 117.84 | 94.67 | 78.44 | 48.06 | Upgrade
|
| Gross Profit | -74.85 | -96.95 | -86.75 | -48.88 | -45.25 | -26.68 | Upgrade
|
| Selling, General & Admin | 42.05 | 42.08 | 42.79 | 33.25 | 15.2 | 8.77 | Upgrade
|
| Operating Expenses | 42.05 | 42.08 | 42.79 | 33.25 | 15.2 | 8.77 | Upgrade
|
| Operating Income | -116.9 | -139.03 | -129.53 | -82.13 | -60.45 | -35.45 | Upgrade
|
| Interest Expense | - | -1.37 | -2.22 | -2.15 | -1.23 | - | Upgrade
|
| Interest & Investment Income | 8.83 | 6.03 | 4.29 | 2.27 | 0.3 | 2.49 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | -5.68 | - | Upgrade
|
| EBT Excluding Unusual Items | -108.07 | -134.38 | -127.46 | -82.01 | -67.06 | -32.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.28 | 3.78 | -0.71 | -1.88 | 0.1 | -0.33 | Upgrade
|
| Other Unusual Items | - | -0.62 | - | - | - | - | Upgrade
|
| Pretax Income | -105.22 | -131.21 | -128.18 | -83.89 | -66.96 | -33.3 | Upgrade
|
| Income Tax Expense | 0.28 | 1.28 | - | - | -0.63 | 0.8 | Upgrade
|
| Net Income | -105.5 | -132.49 | -128.18 | -83.89 | -66.34 | -34.1 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 8.47 | Upgrade
|
| Net Income to Common | -105.5 | -132.49 | -128.18 | -83.89 | -66.34 | -42.57 | Upgrade
|
| Shares Outstanding (Basic) | 65 | 50 | 49 | 46 | 11 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 65 | 50 | 49 | 46 | 11 | 1 | Upgrade
|
| Shares Change (YoY) | 31.51% | 1.59% | 6.12% | 304.93% | 728.80% | 6.09% | Upgrade
|
| EPS (Basic) | -1.63 | -2.67 | -2.62 | -1.82 | -5.83 | -31.03 | Upgrade
|
| EPS (Diluted) | -1.63 | -2.67 | -2.62 | -1.82 | -5.83 | -31.03 | Upgrade
|
| Free Cash Flow | -71.58 | -108.55 | -111.44 | -88.24 | -67.9 | 54.27 | Upgrade
|
| Free Cash Flow Per Share | -1.11 | -2.19 | -2.28 | -1.92 | -5.97 | 39.55 | Upgrade
|
| Gross Margin | -222.31% | - | -278.96% | -106.76% | -136.30% | -124.77% | Upgrade
|
| Operating Margin | -347.20% | -669.84% | -416.56% | -179.39% | -182.10% | -165.81% | Upgrade
|
| Profit Margin | -313.35% | -638.34% | -412.19% | -183.23% | -199.83% | -199.09% | Upgrade
|
| Free Cash Flow Margin | -212.59% | -522.96% | -358.36% | -192.73% | -204.55% | 253.80% | Upgrade
|
| EBITDA | -115.13 | -137.15 | -127.86 | -80.64 | -58.83 | -33.86 | Upgrade
|
| EBITDA Margin | - | - | - | -176.13% | -177.23% | -158.35% | Upgrade
|
| D&A For EBITDA | 1.77 | 1.88 | 1.68 | 1.49 | 1.62 | 1.6 | Upgrade
|
| EBIT | -116.9 | -139.03 | -129.53 | -82.13 | -60.45 | -35.45 | Upgrade
|
| EBIT Margin | - | - | - | -179.39% | -182.10% | -165.81% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.